Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.40 |
| ▸ | HTR3B | O95264 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014770 | 0.79 | CYP11B1 (0.39) | PDE10AKDM4EKMT2A | |
| SCHEMBL21730194 | 0.77 | CTSS (0.46) | PDE10AKDM4EL3MBTL1KMT2ACNR1 | |
| SCHEMBL29907703 | 0.77 | CTSS (0.46) | PDE10AKDM4EL3MBTL1KMT2ACNR1 | |
| SCHEMBL15539388 | 0.77 | PDE10A (0.41) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2949577 | 0.76 | CTSS (0.45) | PDE10AKDM4EL3MBTL1HSD11B1CNR1 | |
| SCHEMBL2714682 | 0.76 | HPGD (0.41) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15918558 | 0.75 | HTR3E (0.50) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6861227 | 0.75 | GRM5 (0.42) | KDM4EKMT2A | |
| SCHEMBL21730383 | 0.74 | CTSS (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6838679 | 0.73 | HSD11B1 (0.50) | PDE10AHTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854804-B1 | PYRROLIDINO HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| CN-104363908-B | pyrrolidinyl heterocyclic | 霍夫曼-拉罗奇有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-9540384-B2 | Pyrrolidino heterocycles | HOFFMANN-LA ROCHE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2854804-A1 | PYRROLIDINO HETEROCYCLES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| CN-104363908-A | Pyrrolidino heterocycles | HOFFMANN LA ROCHE | 2015-02-18 | — | — | CN | disclosed |
| WO-2013178569-A1 | PYRROLIDINO HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | PDE3A, PDE3B, PDE2A | PDE10A 5/4885HTR3E 2232/4885HTR3B 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.